Arvinas, Inc. (ARVN) Q2 FY26 Earnings Call

Multiple clinical catalysts are funded through 2028, but ARV-102 trial starts slipped to 2027 and ARV-393’s 2026 data are mostly subtherapeutic.

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-08-04
Length48 minutes
EPS$2.58
Revenue$249.7M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q1 FY26

All ARVN earnings · Back to ARVN overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.